ライブ
FierceBiotechBig Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic deliveryClinical OMICsPhase Ib/IIa for Hepatitis B Epigenetic Silencer Shows Best-in-Class PotentialFierceBiotechEthyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s TepezzaEndpoints NewsShattuck raises $75M; Servier inks neuro ASO pact with n-Lorem FoundationEndpoints NewsBiotech pay analysis: 12 execs with $35M+ M&A golden parachutesBioPharma DiveAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineFierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BBioWorldShenzhen Chipscreen Biosciences synthesizes new HDAC inhibitorsBioWorldKunming Taita Biotech discovers new angiogenesis inhibitorsBioWorldJiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonistsBioWorldColumbia researchers use base editing to modify human embryo genomeLabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035
BioWorld 2026年1月6日

Scinopharm wins US FDA approval of multiple sclerosis drug

Scinopharm wins US FDA approval of multiple sclerosis drug

原文
本文は利用できません。元の情報源をご確認ください。